Lutonix® DCB for Treatment of Long Lesions in Femoropopliteal Arteries

CompletedOBSERVATIONAL
Enrollment

125

Participants

Timeline

Start Date

December 31, 2013

Primary Completion Date

May 23, 2016

Study Completion Date

June 13, 2018

Conditions
Femoral Artery OcclusionFemoral Arterial Stenosis
Interventions
DEVICE

Lutonix Paclitaxel Drug Coated Balloon (DCB)

Patients exposed to the DCB as part of their routine care.

Trial Locations (14)

2020

ZNA-Campus Middelheim, Antwerp

2650

UZA Antwerp University Hospital, Edegem

3600

Ziekenhuis Oost Limburg, Genk

6000

Luzerner Kantonsspital, Division of Angiology, Lucerne

8036

LKH-Univ. Klinikum Graz, Graz

8500

AZ Groeninge, Kortrijk

10365

Ev.Krankenhaus Königin Elisabeth, Berlin

20099

Asklepios Klinik St. Georg, Hamburg

33404

CHU Bordeaux, Talence

48149

Westfälische Wilhelms-Universität Münster, Münster

69120

University Clinical Center Heidelberg, Heidelberg

72076

Universitätsklinikum Tübingen, Tübingen

93049

Krankenhaus Barmherzige Brüder Regensburg, Regensburg

96515

Medinos Kliniken Sonneberg, Sonneberg

Sponsors

Lead Sponsor

All Listed Sponsors
lead

C. R. Bard

INDUSTRY

NCT02013271 - Lutonix® DCB for Treatment of Long Lesions in Femoropopliteal Arteries | Biotech Hunter | Biotech Hunter